Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 10/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454450 | 0.90 | PRKDC (0.48) | PRKDCKITFLT3POLBALDH1A1 | |
| SCHEMBL14802153 | 0.88 | PRKDC (0.61) | PRKDCPOLB | |
| SCHEMBL14468620 | 0.88 | PRKDC (0.47) | PRKDC | |
| SCHEMBL14447683 | 0.87 | PRKDC (0.46) | PRKDC | |
| SCHEMBL14802154 | 0.86 | PRKDC (0.46) | PRKDC | |
| SCHEMBL14802146 | 0.85 | PRKDC (0.47) | PRKDCPOLBALDH1A1LMNAGAA | |
| SCHEMBL5440528 | 0.84 | PRKDC (0.42) | PRKDCKITFLT3 | |
| SCHEMBL5446334 | 0.82 | PRKDC (0.51) | PRKDC | |
| SCHEMBL14802156 | 0.81 | PRKDC (0.59) | PRKDC | |
| SCHEMBL5448696 | 0.80 | PRKDC (0.61) | PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | DCK, DTYMK, XPA | PRKDC 12/4885KIT 2595/4885FLT3 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.